Skip to main content

Table 5 Multivariable univariable Cox regression models for new onset cardiac complication outcome and all-cause mortality in the matched cohort

From: Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysis

Model 1

All-cause mortality

HR [95% CI];P value

Composite outcome

HR [95% CI];P value

Characteristics

PD-L1 v.s. PD-1

0.80[0.64-0.99];0.0389*

0.34[0.18-0.64];0.0009***

PD-L1 expenditure, HKD

1.000[1.000-1.0001];<0.0001***

1.000[1.000-1.000];0.0592

Total PD-L1 dose amount, mg

1.000[1.000-1.000];0.0728

1.000[1.000-1.000];0.2615

PD-L1 inhibitors duration, days

1.00[0.99-1.001];<0.0001***

0.99[0.99-1.00];0.0301*

PD-1 expenditure, HKD

1.000[1.000-1.0001];<0.0001***

1.000[1.000-1.0001];0.0014**

Total PD-1 dose amount (mg)

1.000[1.000-1.0001];0.0005***

1.000[1.000-1.000];0.1100

PD-1 inhibitors duration, days

0.998[0.997-0.998];<0.0001***

0.998[0.997-0.999];0.0006***

Model 2

All-cause mortality

HR [95% CI];P value

Composite outcome

HR [95% CI];P value

Characteristics

PD-L1 v.s. PD-1

0.79[0.61-0.99];0.0366*

0.34[0.16-0.65];0.0009***

PD-L1 expenditure, HKD

1.000[1.000-1.0001];<0.0001***

1.000[1.000-1.000];0.0528

Total PD-L1 dose amount, mg

1.000[1.000-1.000];0.0740

1.000[1.000-1.000];0.2448

PD-L1 inhibitors duration, days

1.00[0.99-1.00];<0.0001***

0.99[0.99-1.00];0.0295*

PD-1 expenditure, HKD

1.000[1.000-1.0001];<0.0001***

1.000[1.000-1.0001];0.0012**

Total PD-1 dose amount (mg)

1.000[1.000-1.0001];0.0007***

1.000[1.000-1.000];0.1334

PD-1 inhibitors duration, days

0.998[0.997-0.998];<0.0001***

0.998[0.997-0.999];0.0007***

Model 3

All-cause mortality

HR [95% CI];P value

Composite outcome

HR [95% CI];P value

Characteristics

PD-L1 v.s. PD-1

0.81[0.64-0.98];0.0322*

0.33[0.18-0.63];0.0007***

PD-L1 expenditure, HKD

1.000[1.000-1.0001];<0.0001***

1.000[1.000-1.0001];0.0433*

Total PD-L1 dose amount, mg

1.000[1.000-1.000];0.0733

1.000[1.000-1.000];0.2482

PD-L1 inhibitors duration, days

1.00[1.00-1.001];<0.0001***

0.99[0.99-1.00];0.0282*

PD-1 expenditure, HKD

1.000[1.000-1.0001];<0.0001***

1.000[1.000-1.0001];0.0020**

Total PD-1 dose amount (mg)

1.000[1.000-1.0001];0.0008***

1.000[1.000-1.000];0.1673

PD-1 inhibitors duration, days

0.998[0.997-0.998];<0.0001***

0.998[0.997-0.999];0.0008***

  1. Model 1 adjusted for significant demographics
  2. Model 2 adjusted for significant demographics, and past comorbidities
  3. Model 3 adjusted for significant demographics, past comorbidities, and non-PD-L1/PD-1 medications
  4. * for p≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001; HR: Hazard ratio; CI: Confidence interval; APTT: applied partial thromboplastin test; PD-1: Programmed death 1 inhibitors; PD-L1: programmed death 1 ligand inhibitors; IR: incidence rate
Back to article page

Cardio-Oncology

ISSN: 2057-3804

Contact us